Original Article

Enlargement Ratio May Predict Device Size in Elderly Patients with Atrial Septal Defect

Semi Ozturk , MD¹, Ahmed Seyfettin Gurbuz, MD², Suleyman Cagan Efe, MD³, Mehmet Fatih Yilmaz, MD⁴, and Cevat Kirma, MD⁴

¹Department of Cardiology, Haseki Training and Research Hospital, Istanbul, Turkey

²Department of Cardiology, Yunus Emre State Hospital, Eskişehir, Turkey

³Department of Cardiology, Ağrı State Hospital, Ağrı, Turkey

⁴Department of Cardiology, Kartal Koşuyolu Heart Training and Research Hospital, Istanbul, Turkey

Received: Apr 3, 2017

Revised: May 14, 2017

Accepted: May 31, 2017

Correspondence to

Semi Ozturk, MD

Department of Cardiology, Haseki Training and Research Hospital, Millet Caddesi Aksaray/ Fatih, Istanbul 34130, Turkey.

Tel: +90-212-529-4400

Fax: +90-212-589-6229

E-mail: semi_ozturk@yahoo.com

Copyright © 2017. The Korean Society of Cardiology

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ORCID iDs

Semi Ozturk

<https://orcid.org/0000-0001-5696-6849>

Conflict of Interest

The authors have no financial conflicts of interest.

ABSTRACT

Background and Objectives: Balloon sizing remains the main technique for determining occluder device size for atrial septal defects (ASDs). New evidence has proposed that accurate estimation of device size could be possible without using the balloon technique. Operators have predicted the amount of possible enlargement depending on their experiences. Thus, selection criteria have mostly relied on personal observations and experiences. The objective of this study was to determine the relationship between age, sex, defect size, and deployed device size based on the balloon technique.

Subjects and Methods: Sixty-six patients who underwent percutaneous ASD closure with a Cardi-O-Fix occluder between 2011 and 2012 were retrospectively evaluated. Patients whose maximum defect size and device size were available were included. Enlargement amount (EA) (device size–defect size) and enlargement ratio (ER) (EA/defect size) were calculated. The relationship between these 2 calculations and age, sex, and defect size were analyzed.

Results: EA and ER were 5.2±3.6 mm (min: 0, max: 15, median: 5) and 39.3%±31.5% (min: 0, max: 125, median: 32), respectively. EA and ER did not differ between genders ($p=0.800$; $p=0.430$). EA and ER were not correlated with maximum defect size ($p=0.310$; $p=0.050$). EA and ER showed no correlation with age ($p=0.970$; $p=0.640$). However when patients were dichotomized based on age 40, ER was significantly lower in older group ($p=0.030$). Unexpectedly, no difference was observed between the 2 groups in terms of EA ($p=0.110$). Size of deployed device had a strong correlation with defect size measured with two-dimensional (2D) transesophageal echocardiography (TEE; device size=1.1177×TEE defect size+3.5297; $R=0.84$; $p<0.010$).

Conclusion: EA and ER did not show a significant correlation with sex and defect size in our study. Patients older than 40 had a significantly lower ER compared to younger patients. Device size was strongly correlated with defect size measured with TEE.

Keywords: Heart septal defects, atrial; Heart defects, congenital; Echocardiography

INTRODUCTION

Atrial septal defects (ASDs) are the most common congenital defects in adults following bicuspid aortic valve defects. Prevalence is about 2 per 1,000 live births. ASDs comprise 13% of all congenital defects.¹⁾ Morbidity and mortality of ASDs are well documented when

left untreated. Percutaneous treatment, which is accepted as the first option today, was first performed just 10 years after surgical treatment methods matured.²⁾ Percutaneous treatment was performed under fluoroscopy for many years until the evolution of echocardiography. Operators have had so much experience with transesophageal echocardiography (TEE) that today transthoracic echocardiography (TTE) is a common procedure.

Although both short- and long-term follow-up results of percutaneous treatment are quite satisfactory, concerns have been raised regarding aortic erosion in the last few years.³⁾ Since erosion may depend on device size, size calculations based on classically accepted balloon sizing are questioned. Instead of balloon sizing, many operators predict device size by adding constant numbers to the meticulously evaluated defect size using transesophageal echocardiography.⁴⁾ This method may be most accurately used with three-dimensional (3D) transesophageal echocardiography which evaluates ASD dimensions most precisely. However, these constant numbers still rely on operator experience and not on scientific calculations. Although short-term results of this method seem successful, erosive complications should be followed up before the method suggested.

The atrial septum is an elastic structure which is permitted to distend. However, our experience suggests distensibility of the atrial septum differs between patients. Several factors may affect elastic tissue including age and genetic factors. In this study, we aimed to examine the relationship between age, sex, defect size, and atrial septum distensibility. We aim to guide operators when selecting devices depending on scientific criteria.

SUBJECTS AND METHODS

We retrospectively analyzed patients that underwent percutaneous ASD closure in our clinic at the Kartal Koşuyolu Heart Training and Research Hospital between January 2011 and December 2012. The study was approved by the local ethical committee. The study included patients whose ASDs were closed with Cardi-O-Fix (Starway Medical Technology, Inc., Beijing, China). Patients were included whose maximum defect size and device size were available. Finally, data for 66 patients were available and included in this study.

A two-dimensional (2D) TEE (Philips iE33; Philips Medical Systems, Andover, MA, USA) was used for pre-procedural evaluation. The procedure was performed with either TTE or TEE. When TTE was used, the patient was sedated. General anesthesia was used when the procedure was performed with TEE. Independent of defect and rim sizes, the balloon sizing technique was used in all procedures. Indentation on the slowly inflated balloon was measured under fluoroscopy. Thus, over-inflation of the balloon and overstretching of the defect were avoided. The same size device as the stretched defect size was used if available. A one size bigger device was used in instances when the same size was not available. Thus, a 2 mm bigger device than the stretched size could be implanted. The difference between device size and pre-procedural maximum defect size was accepted as the enlargement amount (EA). Hence enlargement ratio (ER) was acquired via dividing the EA by the pre-procedural maximum defect size. Calculations were formulated as follows:

$$EA = \text{device size} - \text{maximum defect size}$$

$$ER = EA / \text{maximum defect size}$$

Association of age, sex, and preprocedural maximum defect size with enlargement size and ratio were analyzed.

Statistical analyses

Statistical analyses were performed using SPSS 17.0 (SPSS Inc., Chicago, IL, USA). The Kolmogorov-Smirnov test was used to analyze data normality. Continuous data were expressed as mean±standard deviation (SD), and categorical data were expressed as percentages. The χ^2 test was used to assess differences in categorical variables between groups. The relationships between parameters were assessed using Pearson's or Spearman's correlation analyses according to the normality of the data. Differences between patient subgroups were tested using the Mann-Whitney U or Student's t-tests where appropriate p value <0.050 was considered statistically significant.

RESULTS

A total of 66 patients, 19 (29%) male and 47 (71%) female aged 35.3±14.3 (min: 4, max: 65, median: 35.5) were included in this study. The study group included 4 children aged 4, 7, 13, and 15 years. The body mass index (BMI) for males and females was 25.5±5.5 and 25.1±4.2, respectively (p=0.850). Clinical presentations were as follows: 34 (51%) patients with dyspnea/fatigue, 12 (18%) patients with palpitation, 5 (7%) patients with chest pain, 1 patient with transient ischemic episode, 1 patient with cough, and 12 (18%) patients were asymptomatic. Only 1 patient had atrial fibrillation; the other 65 patients had sinus rhythm. Six patients had complete and 2 patients had incomplete right bundle branch block (RBBB) in electrocardiogram (ECG). Forty-seven (71%) patients had at least 1 of the echocardiographic findings of right atrial, right ventricular or pulmonary artery dilation and pulmonary artery pressure >36 mmHg. Forty (61%) procedures were performed with TEE and 26 (39%) with TTE. The success of percutaneous closure was 100%. Follow-up interval was 28±6 months. Residual shunt was detected in 2 (3%) patients and disappeared at follow-up. One patient had pericardial effusion which later disappeared. Early or late embolization did not occur.

ASD size was 14.1±5.1 mm. Defect sizes for males and females were 13.7±4.4 mm (min: 7, max: 30, median: 14) and 15.7±6.4 mm (min: 6, max: 25, median: 13), respectively. ASD size was not different between the sexes (p=0.280). EA was 5.2±3.6 mm (min: 0, max: 15, median: 5) (**Table 1**). EA was not significantly different between the sexes (p=0.800). EA was not correlated with age or defect size (p=0.970; p=0.050). ER was 39.3%±31.5% (min: 0, max: 125, median: 32). Female and male ERs were 41.3%±32.3% and 34.5%±29.8%, respectively. ER did not differ between the sexes (p=0.430). ER was not significantly correlated with age and defect size (p=0.640; p=0.310). ER was less than 50% in 22 (88%) of 25 patients above 40 years of age (**Figure 1**). Patients were classified into younger and older groups with 40 as the cut-off.

Table 1. Baseline characteristics

Characteristics	Male (n=19)	Female (n=47)	p value
Age (years)	37.4±15.0	34.5±14.1	0.480
BMI (kg/m ²)	25.5±5.5	25.1±4.2	0.850
Defect size (mm)	14 (7, 30)	13 (6, 25)	0.280
EA (mm)	4 (0, 15)	5 (0, 13)	0.800
ER (%)	30.0 (0, 115)	33.3 (0, 125)	0.430

Values are presented as mean±SD or median (min, max).

BMI = body mass index; EA = enlargement amount; ER = enlargement ratio; SD = standard deviation.

Figure 1. ER-age distribution.
ER = enlargement ratio.

The ER of young and old patients was $46.8\% \pm 35.3\%$ and $27.1\% \pm 18.8\%$, respectively, which was significantly different between the 2 groups ($p=0.030$). However, there were no differences between the 2 groups in terms of defect size and EA ($p=0.120$; $p=0.110$) (**Table 2**). The size of the deployed device was strongly correlated with defect size measured with 2D TEE (device size = $1.1177 \times \text{TEE defect size} + 3.5297$; $R=0.84$; $p<0.010$) (**Figure 2**).

DISCUSSION

We concluded that ER was lower in patients older than 40 years. Extracellular matrix regeneration ability tends to decrease with increased age which may result in loss of atrial septal elasticity. Probably atherosclerotic factors like diabetes, hypertension, dyslipidemia, and smoking could accompany a stiffened atrial septum. Since patients were rarely exposed to these degenerative factors before the 4th decade, we did not expect to see a linear relationship between ER and age.

Mean difference between deployed devices and maximal defect diameter was 5.2 ± 3.6 . Deployed devices were approximately 40% bigger than the defects. Although both EA and ER were widely dispersed, the ER in older patients was lower by approximately 27%. EA was not different between our groups despite the fact that defect sizes were similar. Mean values seemed to be similar to studies which used putative values to calculate device size without

Table 2. ASD characteristics of young and older patients

Characteristics	Age >40 (n=25)	Age ≤40 (n=41)	p value
Defect size (mm)	15 (8, 25)	13 (6, 30)	0.120
EA (mm)	4 (0, 9)	5 (0, 15)	0.110
ER (%)	27.3 (0, 88)	38.5 (0, 125)	0.030

Values are presented as median (min, max).

ASD = atrial septal defect; EA = enlargement amount; ER = enlargement ratio.

Figure 2. Device and ASD size* correlation.

ASD = atrial septal defect; TEE = transesophageal echocardiography.

*TEE measurement.

using balloon sizing.⁴⁾ However, a wide range of values (min: 0, max: 15, median: 5) calculated in our study made it difficult to accept the mean value to decide device size. Despite this study restriction, it could be concluded that device size estimation without balloon dilatation would be feasible in older patients due to a stable ER (27%) and range (0–88).

Residual shunt and embolization ratios were compatible with other studies in the literature.⁵⁾ This could be attributed to the precision of balloon sizing. Though higher ERs in patients younger than 40 can be explained by increased elasticity, doubt arising from overstretching is a factor which cannot be thoroughly eliminated. Although good correlation between device size and defect size is an indirect proof of precise balloon sizing, overstretching was strictly avoided. There may be another under-emphasized reason for over enlarging other than balloon over-dilatation. Non-circular ASDs were reported in up to 42% of different studies.^{6,7)} Most of these defects are oval shaped rather than circle shaped which means these defects have 2 radii that are markedly different from each other. The balloon dilatation pattern of an oval shaped defect is evidently different from a circle shaped defect. A small radius tends to enlarge more compared with a large radius. Exact circular defects enlarge equally along both radii. Thus, circular defects enlarge more compared with oval defects. We lacked 3D data that could determine the impact of this intrinsic shape effect.

Defect sizes measured with 2D TEE are well correlated with devices and this can be mathematically formulated (device size=1.1177×TEE defect size+3.5297; R=0.84; p<0.010). Depending on this finding, it could be concluded that defect size is the most reliable measurement which guides device size estimation. Although the mathematical formula is strong, it is not possible to anticipate EAs and ERs when defects are observed one by one. Probably there are plenty of factors affecting enlargement parameters which make it impossible to include them all in a mathematical equation. The 3D structure of the defect could be much more important than any other factors. Despite these estimations and

calculations, the experience of the operator in a particular technique still seems to be more decisive than other factors.

Although 4 decades have passed since the first percutaneous ASD closure and experience has increased tremendously, there is still debate about correct calculation of device size. The balloon sizing technique was accepted as the gold standard for determining device size since the first cases. The majority of operators still use balloon sizing and TEE conservatively. Du et al.⁸⁾ observed 138 percutaneously closed defects and compared the differences between balloon sizing measurements and defects. They proposed the same size with an inflated balloon or a larger device up to 2 mm would be suitable for closure. In a study including 51 patients, Helgason et al.⁹⁾ found significant discordance between defect sizes measured with 2D TEE and devices. Thus, they proposed that device deployment depending solely on defect size was not safe. In another study, ASDs of 41 patients were evaluated with 2D and 3D TEE and balloon sizing. The largest measurement was obtained with balloon dilatation, whereas the smallest was obtained with 2D TEE. 3D TEE measurements were so compatible with balloon sizing measurements that the study suggested 3D measurement could be used instead of balloon sizing. This study reported a similar correlation between 3D TEE and balloon sizing.¹⁰⁾ However, that study emphasized 3D TEE would not be used as an alternative for balloon sizing, but rather could be used complementarily. Chien et al.¹¹⁾ compared balloon sizing measurements with intracardiac echocardiography (ICE), 2D TEE, TTE, and angiography. Measurements with ICE correlated best with balloon sizing. Carlson et al.¹²⁾ compared 2 different balloon sizing techniques. A compliant balloon was inflated until a significant waist appeared in 74 patients in the first group. The balloon was inflated till flow through the defect disappeared in 43 patients, but no waist appeared in the second group; later this technique was named, stop-flow. Five complications occurred in the first technique, suggesting overstretching may not be as safe as thought before. Wang et al.⁴⁾ conducted a study in order to clarify whether it was possible to precisely decide device size without balloon sizing. They compared 243 patients who underwent the procedure without balloon sizing and 271 patients with balloon sizing. In the group where balloon sizing was not used, the size of devices selected was 4–6 mm larger than the maximal diameter in case the defect was smaller than 14 mm and 5–8 mm larger in case the defect was equal to or larger than 14 mm. Closure and complication rates were similar between the 2 groups suggesting balloon inflation may not be necessary. Two embolizations occurred in each group, whereas no embolizations occurred in our study, though subject number was not sufficient to compare the studies. This finding may be attributed to the precision of balloon sizing in our study.

Two hundred thirty-four thousand atrial septal occluder (ASO) devices were used until 2011 since Food and Drug Administration (FDA) approval in 2002. The number of reported erosive complications was more than 100 with an incidence of approximately 0.1%–0.3%.¹³⁾ The underlying etiology was not thoroughly clarified due to the rarity of complications. However, concerns raised about overstretching of the defect during balloon sizing resulting in larger device selection would be the underlying mechanism of erosion. Despite these concerns, the evidence is not enough sufficient to stop using balloon sizing. We perform balloon sizing rigorously so that we inflate the balloon slowly and do not inflate after a waist appears.

The retrospective nature of this study was a limitation for identifying balloon stretch diameters, thus more information is needed. We did not have a control group that was treated without balloon sizing. A paucity of child patients may also limit our ability to generalize this data.

In conclusion, we concluded that EA and ER were not associated with sex and defect size. However, ER was significantly larger in patients older than 40. Selected device size was correlated with maximal defect size measured on 2D TEE. Our results suggest it would be more appropriate to close ASDs without balloon sizing in older patients.

REFERENCES

1. van der Linde D, Konings EE, Slager MA, et al. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. *J Am Coll Cardiol* 2011;58:2241-7.
[PUBMED](#) | [CROSSREF](#)
2. King TD, Thompson SL, Steiner C, Mills NL. Secundum atrial septal defect. Nonoperative closure during cardiac catheterization. *JAMA* 1976;235:2506-9.
[PUBMED](#) | [CROSSREF](#)
3. McElhinney DB, Quartermain MD, Kenny D, Alboliras E, Amin Z. Relative risk factors for cardiac erosion following transcatheter closure of atrial septal defects: a case-control study. *Circulation* 2016;133:1738-46.
4. Wang JK, Tsai SK, Lin SM, Chiu SN, Lin MT, Wu MH. Transcatheter closure of atrial septal defect without balloon sizing. *Catheter Cardiovasc Interv* 2008;71:214-21.
[PUBMED](#) | [CROSSREF](#)
5. Egred M, Andron M, Albouaini K, Alahmar A, Grainger R, Morrison WL. Percutaneous closure of patent foramen ovale and atrial septal defect: procedure outcome and medium-term follow-up. *J Interv Cardiol* 2007;20:395-401.
[PUBMED](#) | [CROSSREF](#)
6. Song J, Lee SY, Baek JS, Shim WS, Choi EY. Outcome of transcatheter closure of oval shaped atrial septal defect with amplatzer septal occluder. *Yonsei Med J* 2013;54:1104-9.
[PUBMED](#) | [CROSSREF](#)
7. Kim KH, Song J, Kang IS, Chang SA, Huh J, Park SW. Balloon occlusive diameter of non-circular atrial septal defects in transcatheter closure with amplatzer septal occluder. *Korean Circ J* 2013;43:681-5.
[PUBMED](#) | [CROSSREF](#)
8. Du ZD, Cao QL, Rhodes J, Heitschmidt M, Hijazi ZM. Choice of device size and results of transcatheter closure of atrial septal defect using the amplatzer septal occluder. *J Interv Cardiol* 2002;15:287-92.
[PUBMED](#) | [CROSSREF](#)
9. Helgason H, Johansson M, Söderberg B, Eriksson P. Sizing of atrial septal defects in adults. *Cardiology* 2005;104:1-5.
[PUBMED](#) | [CROSSREF](#)
10. Zhu W, Cao QL, Rhodes J, Hijazi ZM. Measurement of atrial septal defect size: a comparative study between three-dimensional transesophageal echocardiography and the standard balloon sizing methods. *Pediatr Cardiol* 2000;21:465-9.
[PUBMED](#) | [CROSSREF](#)
11. Chien JC, Hwang B, Fu YC, Lee PC, Hsieh KS, Jan SL. Sizing of atrial septal defects by intracardiac echocardiography for device closures. *J Chin Med Assoc* 2008;71:399-405.
[PUBMED](#) | [CROSSREF](#)
12. Carlson KM, Justino H, O'Brien RE, et al. Transcatheter atrial septal defect closure: modified balloon sizing technique to avoid overstretching the defect and oversizing the Amplatzer septal occluder. *Catheter Cardiovasc Interv* 2005;66:390-6.
[PUBMED](#) | [CROSSREF](#)
13. U.S. Food and Drug Administration. Rare serious erosion events associated with St. Jude Amplatzer Atrial Septal Occluder (ASO): FDA safety communication [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2013 [cited year month day]. Available from: <http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm371145.htm>.